199POutcome of non-metastatic male breast cancer: 222 patients

199POutcome of non-metastatic male breast cancer: 222 patients

Abstract Background There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser: Arslan, U Y, Aslan, F, Ayhan, M, Akdeniz, N, Tahtacı, G, Çınkır, H Yeşil, inanc, M, Imamoglu, G I, Alkış, N, Turan, N, Kaplan, M A, ozdemir, N Y, Oksuzoglu, O B Cakmak
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_5
container_start_page
container_title Annals of oncology
container_volume 30
creator Arslan, U Y
Aslan, F
Ayhan, M
Akdeniz, N
Tahtacı, G
Çınkır, H Yeşil
inanc, M
Imamoglu, G I
Alkış, N
Turan, N
Kaplan, M A
ozdemir, N Y
Oksuzoglu, O B Cakmak
description Abstract Background There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival in operable MBC. Methods The medical records of 261 MBC pts followed between 1986-2018 at 8 cancer center were reviewed retrospectively. 222 patients had non-metastatic MBC at the time of diagnosis were included in current study. Results Median age was 61(29-91) years. Median follow-up 55(1-275)months(mths). %91 of the pts had invasive ductal carcinoma. Also, 30.6% had T3-4 tumors. About half of study group had axillary lymph node-positive tumors. The proportion of positivity of ER, PgR and HER2 status were % 82.5, 73.1 and %18.4. Ten pts had TN MBC. 55 of pts had at least one comorbid chronic illness. 83.9 % of pts had modified radical mastectomy(MRM). 79.9% of pts received adjuvant radiotherapy. Adjuvan hormonotherapy were advised for %78.8, whereas adjuvant chemotherapy(CT) for 71.2 % of the pts(CMF 10.6%, adjuvant trastuzumab %7.5 and antracycline and/or taxane based 81.9% ). 9 HER2-positive pts had no adjuvant CT. Locoregional and/or distant recurrence rate was 36.9%. 77 (34.5%) pts died during follow-up. 52 of them died from metastatic breast cancer. 5-year disease-free survival(DFS) was found to be 66.6 % whereas overall survival(OS) was 73.5 %. Patients with stage I/II tumor were significantly longer DFS as compared to pts had stage III MBC( median not reached vs 78 mths, P
doi_str_mv 10.1093/annonc/mdz240.024
format Article
fullrecord <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdz240_024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdz240.024</oup_id><sourcerecordid>10.1093/annonc/mdz240.024</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdz240_0243</originalsourceid><addsrcrecordid>eNqVzr0KwjAUBeAgCtafB3DLA5j2Jv3ROLiI4qaDe4gxhUqTliYd9OmN1Bdwuhzu4fAhtKIQU-BpIq1trErM480yiIFlIxTRvOBkCxkdowg4S8kmT7Mpmjn3BICCMx6hPeX8eum9aozGTYnDCjHaS-elrxQ2stb43umQsZJW6W6HGWO4DV9tvVugSSlrp5e_O0fr0_F2OJOmb0XbVUZ2L0FBfI1iMIrBKIIx_bP-AWBRRVA</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>199POutcome of non-metastatic male breast cancer: 222 patients</title><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Arslan, U Y ; Aslan, F ; Ayhan, M ; Akdeniz, N ; Tahtacı, G ; Çınkır, H Yeşil ; inanc, M ; Imamoglu, G I ; Alkış, N ; Turan, N ; Kaplan, M A ; ozdemir, N Y ; Oksuzoglu, O B Cakmak</creator><creatorcontrib>Arslan, U Y ; Aslan, F ; Ayhan, M ; Akdeniz, N ; Tahtacı, G ; Çınkır, H Yeşil ; inanc, M ; Imamoglu, G I ; Alkış, N ; Turan, N ; Kaplan, M A ; ozdemir, N Y ; Oksuzoglu, O B Cakmak</creatorcontrib><description>Abstract Background There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival in operable MBC. Methods The medical records of 261 MBC pts followed between 1986-2018 at 8 cancer center were reviewed retrospectively. 222 patients had non-metastatic MBC at the time of diagnosis were included in current study. Results Median age was 61(29-91) years. Median follow-up 55(1-275)months(mths). %91 of the pts had invasive ductal carcinoma. Also, 30.6% had T3-4 tumors. About half of study group had axillary lymph node-positive tumors. The proportion of positivity of ER, PgR and HER2 status were % 82.5, 73.1 and %18.4. Ten pts had TN MBC. 55 of pts had at least one comorbid chronic illness. 83.9 % of pts had modified radical mastectomy(MRM). 79.9% of pts received adjuvant radiotherapy. Adjuvan hormonotherapy were advised for %78.8, whereas adjuvant chemotherapy(CT) for 71.2 % of the pts(CMF 10.6%, adjuvant trastuzumab %7.5 and antracycline and/or taxane based 81.9% ). 9 HER2-positive pts had no adjuvant CT. Locoregional and/or distant recurrence rate was 36.9%. 77 (34.5%) pts died during follow-up. 52 of them died from metastatic breast cancer. 5-year disease-free survival(DFS) was found to be 66.6 % whereas overall survival(OS) was 73.5 %. Patients with stage I/II tumor were significantly longer DFS as compared to pts had stage III MBC( median not reached vs 78 mths, P&lt;.001). Also, the latter group of pts had worse OS than the first group ( median 103 vs 153 mths, P=.030). Median DFS for pts had MRM was significantly better than patients had limited surgery (one-third of those pts had no axillary dissection)(118 vs 57 mths, P=.002). Two HER2-positive pts treated with adjuvant trastuzumab containing regimen had breast cancer recurrence(n = 11) and alive whereas 9 of 19 pts treated other chemotherapy regimen (All but 2 anthracycline and/or taxane based) had experienced the disease relapse and 7 of them died from MBC. Conclusions Although the adjuvant use of anthracyclines /taxanes and trastuzumab for MBC have increased in the last 10 years, stage at diagnosis is still important prognostic factor for survival in MBC. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz240.024</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2019-10, Vol.30 (Supplement_5)</ispartof><rights>European Society for Medical Oncology 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Arslan, U Y</creatorcontrib><creatorcontrib>Aslan, F</creatorcontrib><creatorcontrib>Ayhan, M</creatorcontrib><creatorcontrib>Akdeniz, N</creatorcontrib><creatorcontrib>Tahtacı, G</creatorcontrib><creatorcontrib>Çınkır, H Yeşil</creatorcontrib><creatorcontrib>inanc, M</creatorcontrib><creatorcontrib>Imamoglu, G I</creatorcontrib><creatorcontrib>Alkış, N</creatorcontrib><creatorcontrib>Turan, N</creatorcontrib><creatorcontrib>Kaplan, M A</creatorcontrib><creatorcontrib>ozdemir, N Y</creatorcontrib><creatorcontrib>Oksuzoglu, O B Cakmak</creatorcontrib><title>199POutcome of non-metastatic male breast cancer: 222 patients</title><title>Annals of oncology</title><description>Abstract Background There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival in operable MBC. Methods The medical records of 261 MBC pts followed between 1986-2018 at 8 cancer center were reviewed retrospectively. 222 patients had non-metastatic MBC at the time of diagnosis were included in current study. Results Median age was 61(29-91) years. Median follow-up 55(1-275)months(mths). %91 of the pts had invasive ductal carcinoma. Also, 30.6% had T3-4 tumors. About half of study group had axillary lymph node-positive tumors. The proportion of positivity of ER, PgR and HER2 status were % 82.5, 73.1 and %18.4. Ten pts had TN MBC. 55 of pts had at least one comorbid chronic illness. 83.9 % of pts had modified radical mastectomy(MRM). 79.9% of pts received adjuvant radiotherapy. Adjuvan hormonotherapy were advised for %78.8, whereas adjuvant chemotherapy(CT) for 71.2 % of the pts(CMF 10.6%, adjuvant trastuzumab %7.5 and antracycline and/or taxane based 81.9% ). 9 HER2-positive pts had no adjuvant CT. Locoregional and/or distant recurrence rate was 36.9%. 77 (34.5%) pts died during follow-up. 52 of them died from metastatic breast cancer. 5-year disease-free survival(DFS) was found to be 66.6 % whereas overall survival(OS) was 73.5 %. Patients with stage I/II tumor were significantly longer DFS as compared to pts had stage III MBC( median not reached vs 78 mths, P&lt;.001). Also, the latter group of pts had worse OS than the first group ( median 103 vs 153 mths, P=.030). Median DFS for pts had MRM was significantly better than patients had limited surgery (one-third of those pts had no axillary dissection)(118 vs 57 mths, P=.002). Two HER2-positive pts treated with adjuvant trastuzumab containing regimen had breast cancer recurrence(n = 11) and alive whereas 9 of 19 pts treated other chemotherapy regimen (All but 2 anthracycline and/or taxane based) had experienced the disease relapse and 7 of them died from MBC. Conclusions Although the adjuvant use of anthracyclines /taxanes and trastuzumab for MBC have increased in the last 10 years, stage at diagnosis is still important prognostic factor for survival in MBC. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.</description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVzr0KwjAUBeAgCtafB3DLA5j2Jv3ROLiI4qaDe4gxhUqTliYd9OmN1Bdwuhzu4fAhtKIQU-BpIq1trErM480yiIFlIxTRvOBkCxkdowg4S8kmT7Mpmjn3BICCMx6hPeX8eum9aozGTYnDCjHaS-elrxQ2stb43umQsZJW6W6HGWO4DV9tvVugSSlrp5e_O0fr0_F2OJOmb0XbVUZ2L0FBfI1iMIrBKIIx_bP-AWBRRVA</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Arslan, U Y</creator><creator>Aslan, F</creator><creator>Ayhan, M</creator><creator>Akdeniz, N</creator><creator>Tahtacı, G</creator><creator>Çınkır, H Yeşil</creator><creator>inanc, M</creator><creator>Imamoglu, G I</creator><creator>Alkış, N</creator><creator>Turan, N</creator><creator>Kaplan, M A</creator><creator>ozdemir, N Y</creator><creator>Oksuzoglu, O B Cakmak</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20191001</creationdate><title>199POutcome of non-metastatic male breast cancer: 222 patients</title><author>Arslan, U Y ; Aslan, F ; Ayhan, M ; Akdeniz, N ; Tahtacı, G ; Çınkır, H Yeşil ; inanc, M ; Imamoglu, G I ; Alkış, N ; Turan, N ; Kaplan, M A ; ozdemir, N Y ; Oksuzoglu, O B Cakmak</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdz240_0243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arslan, U Y</creatorcontrib><creatorcontrib>Aslan, F</creatorcontrib><creatorcontrib>Ayhan, M</creatorcontrib><creatorcontrib>Akdeniz, N</creatorcontrib><creatorcontrib>Tahtacı, G</creatorcontrib><creatorcontrib>Çınkır, H Yeşil</creatorcontrib><creatorcontrib>inanc, M</creatorcontrib><creatorcontrib>Imamoglu, G I</creatorcontrib><creatorcontrib>Alkış, N</creatorcontrib><creatorcontrib>Turan, N</creatorcontrib><creatorcontrib>Kaplan, M A</creatorcontrib><creatorcontrib>ozdemir, N Y</creatorcontrib><creatorcontrib>Oksuzoglu, O B Cakmak</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arslan, U Y</au><au>Aslan, F</au><au>Ayhan, M</au><au>Akdeniz, N</au><au>Tahtacı, G</au><au>Çınkır, H Yeşil</au><au>inanc, M</au><au>Imamoglu, G I</au><au>Alkış, N</au><au>Turan, N</au><au>Kaplan, M A</au><au>ozdemir, N Y</au><au>Oksuzoglu, O B Cakmak</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>199POutcome of non-metastatic male breast cancer: 222 patients</atitle><jtitle>Annals of oncology</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>30</volume><issue>Supplement_5</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Abstract Background There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival in operable MBC. Methods The medical records of 261 MBC pts followed between 1986-2018 at 8 cancer center were reviewed retrospectively. 222 patients had non-metastatic MBC at the time of diagnosis were included in current study. Results Median age was 61(29-91) years. Median follow-up 55(1-275)months(mths). %91 of the pts had invasive ductal carcinoma. Also, 30.6% had T3-4 tumors. About half of study group had axillary lymph node-positive tumors. The proportion of positivity of ER, PgR and HER2 status were % 82.5, 73.1 and %18.4. Ten pts had TN MBC. 55 of pts had at least one comorbid chronic illness. 83.9 % of pts had modified radical mastectomy(MRM). 79.9% of pts received adjuvant radiotherapy. Adjuvan hormonotherapy were advised for %78.8, whereas adjuvant chemotherapy(CT) for 71.2 % of the pts(CMF 10.6%, adjuvant trastuzumab %7.5 and antracycline and/or taxane based 81.9% ). 9 HER2-positive pts had no adjuvant CT. Locoregional and/or distant recurrence rate was 36.9%. 77 (34.5%) pts died during follow-up. 52 of them died from metastatic breast cancer. 5-year disease-free survival(DFS) was found to be 66.6 % whereas overall survival(OS) was 73.5 %. Patients with stage I/II tumor were significantly longer DFS as compared to pts had stage III MBC( median not reached vs 78 mths, P&lt;.001). Also, the latter group of pts had worse OS than the first group ( median 103 vs 153 mths, P=.030). Median DFS for pts had MRM was significantly better than patients had limited surgery (one-third of those pts had no axillary dissection)(118 vs 57 mths, P=.002). Two HER2-positive pts treated with adjuvant trastuzumab containing regimen had breast cancer recurrence(n = 11) and alive whereas 9 of 19 pts treated other chemotherapy regimen (All but 2 anthracycline and/or taxane based) had experienced the disease relapse and 7 of them died from MBC. Conclusions Although the adjuvant use of anthracyclines /taxanes and trastuzumab for MBC have increased in the last 10 years, stage at diagnosis is still important prognostic factor for survival in MBC. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.</abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdz240.024</doi></addata></record>
fulltext fulltext
identifier ISSN: 0923-7534
ispartof Annals of oncology, 2019-10, Vol.30 (Supplement_5)
issn 0923-7534
1569-8041
language eng
recordid cdi_oup_primary_10_1093_annonc_mdz240_024
source Alma/SFX Local Collection; EZB Electronic Journals Library
title 199POutcome of non-metastatic male breast cancer: 222 patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A50%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=199POutcome%20of%20non-metastatic%20male%20breast%20cancer:%20222%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Arslan,%20U%20Y&rft.date=2019-10-01&rft.volume=30&rft.issue=Supplement_5&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz240.024&rft_dat=%3Coup%3E10.1093/annonc/mdz240.024%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdz240.024&rfr_iscdi=true